Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Can the Newly Discovered Obesity Genes Help You Lose Weight?

Page 1 of 2

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)Overweight? You can now officially blame it on your parents. Or at least the genes they passed along to you.

Quite a few research papers published recently have shown that mutations in genes can control your appetite and your ability to burn calories. Genetic makeup affecting a person’s weight isn’t all that surprising, considering that people tend to have weight similar to their parents, but it’s nice to have an increasing body of scientific data to support the observation.

In one study, researchers showed deletions in the Mrap2 gene caused mice to weigh twice as much as their siblings even though they ate the same amount, implying the gene is involved in burning the calories.

Another gene, FTO, has long been linked to obesity, but a recent study showed how mutations in the gene leads to higher weight by increasing the level of ghrelin, a hormone that signals to the brain that you’re hungry.

In a third study, researchers sequenced the SIM1 gene, another gene associated with obesity, in 2,100 patients with severe, early-onset obesity and in 1,680 controls. They discovered 13 different variants in SIM1 in 28 unrelated obese patients, including several that weren’t found in the control patients that reduce the protein’s activity significantly.

A weighty issue
How’s this going to help you lose weight? It can’t. At least not yet.

Figuring out that you have one of these mutations is fairly easy. DNA sequencing is getting cheaper by the day. But it’s not as if you can change your genes. Maybe someday, but I’d guess not in your lifetime.

More likely, though, understanding the biology of obesity can help researchers develop drugs to control appetite and burn calories by interacting with the proteins involved in the metabolism process, especially if doctors know which proteins in the patient are functional.

For instance, a drug that increases FTO activity should lead to decreased appetite. Similarly, increasing Mrap2 activity may increase calories burned.

Like we’ve done already
With our limited knowledge of appetite and metabolism, drugmakers have already developed some drugs to treat obesity.

Eisai and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘ Belviq activates the 5-HT2C receptor, which activates a polypeptide that makes you feel full. It’s easier to lose weight if you don’t feel like eating.

VIVUS, Inc. (NASDAQ:VVUS)‘ Qsymia is a combination of two drugs. Phentermine promotes reduced appetite through the release of catecholamines. The other component, topiramate that’s released over time, was originally developed by Johnson & Johnson to treat epilepsy. It isn’t clear exactly how the drug promotes weight loss, but there’s probably something going on in the brain, as the drug is also used to prevent migraines.

Contrave, being developed by Orexigen Therapeutics, Inc. (NASDAQ:OREX), is also a combination drug containing naltrexone and bupropion, the latter of which was developed by GlaxoSmithKline plc (ADR) (NYSE:GSK) as an antidepressant that is also used to help people stop smoking. Combined, the drugs stimulate pathways that increase energy expenditure and reduce appetite.

Orlistat, which is sold by Roche as Xenical and by GlaxoSmithKline plc (ADR) (NYSE:GSK) as a lower-dose over-the-counter formulation called Alli, reduces caloric intake by blocking the absorption of fats so they pass though the body.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!